T1	tradename 112 120	Oncaspar
T2	tradename 183 191	Oncaspar
T3	tradename 195 203	Oncaspar
T4	nanoparticle 205 218	pegaspargase)
T5	routeofadministration 234 247	intramuscular
T6	routeofadministration 251 262	intravenous
T7	fdaapprovaldate 290 294	1994
T8	tradename 494 494	
T9	chemoclass 501 527	asparagine specific enzyme
T10	indication 647 675	acute lymphoblastic leukemia
T11	indication 691 719	Acute lymphoblastic leukemia
T12	dose 843 871	2,500 International Units/m2
T13	routeofadministration 872 887	intramuscularly
T14	routeofadministration 891 904	intravenously
T15	routeofadministration 964 977	intramuscular
T16	routeofadministration 1119 1130	intravenous
T17	inactiveingredient 1196 1211	sodium chloride
T18	inactiveingredient 1215 1223	dextrose
T19	tradename 1317 1325	Oncaspar
T20	tradename 1714 1722	Oncaspar
T21	activeingredient 1778 1792	L-asparaginase
T22	activeingredient 1850 1864	L-asparaginase
T23	activeingredient 1936 1950	L-asparaginase
T24	adversereaction 2045 2056	Anaphylaxis
T25	adversereaction 2060 2086	serious allergic reactions
T26	tradename 2155 2163	Oncaspar
T27	adversereaction 2181 2208	serious allergic reactions.
T28	adversereaction 2225 2235	Thrombosis
T29	tradename 2250 2258	Oncaspar
T30	adversereaction 2276 2302	serious thrombotic events.
T31	adversereaction 2319 2331	Pancreatitis
T32	adversereaction 2376 2389	pancreatitis.
T33	tradename 2402 2410	Oncaspar
T34	adversereaction 2428 2441	pancreatitis.
T35	adversereaction 2458 2477	Glucose intolerance
T36	adversereaction 2582 2596	Hepatotoxicity
T37	adversereaction 2762 2780	allergic reactions
T38	adversereaction 2792 2804	anaphylaxis)
T39	adversereaction 2806 2919	central nervous system (CNS) thrombosis, coagulopathy, elevated transaminases, hyperbilirubinemia, hyperglycemia,
T40	adversereaction 2924 2937	pancreatitis.
T41	company 2990 3021	Sigma-Tau Pharmaceuticals, Inc.
T42	indication 3282 3316	Acute Lymphoblastic Leukemia (ALL)
T43	indication 3346 3374	Acute Lymphoblastic Leukemia
T44	adversereaction 3867 3878	Anaphylaxis
T45	adversereaction 3883 3909	Serious Allergic Reactions
T46	adversereaction 3952 3962	Thrombosis
T47	adversereaction 4002 4014	Pancreatitis
T48	adversereaction 4020 4046	Serious Allergic Reactions
T49	adversereaction 4052 4071	Glucose Intolerance
T50	adversereaction 4077 4087	Thrombosis
T51	adversereaction 4093 4105	Coagulopathy
T52	adversereaction 4111 4123	Pancreatitis
T53	adversereaction 4129 4143	Hepatotoxicity
T54	adversereaction 4148 4171	Abnormal Liver Function
T55	adversereaction 4177 4196	Glucose Intolerance
T56	adversereaction 4255 4273	Allergic Reactions
T57	indication 4729 4763	Acute Lymphoblastic Leukemia (ALL)
T58	tradename 4764 4772	Oncaspar
T59	indication 4890 4894	ALL.
T60	indication 4900 4928	Acute Lymphoblastic Leukemia
T61	tradename 4966 4974	Oncaspar
T62	indication 5081 5084	ALL
T63	activeingredient 5125 5140	L-asparaginase.
T64	tradename 5216 5224	Oncaspar
T65	dose 5228 5256	2,500 International Units/m2
T66	routeofadministration 5257 5272	intramuscularly
T67	routeofadministration 5277 5291	intravenously.
T68	tradename 5292 5300	Oncaspar
T69	frequency 5348 5362	every 14 days.
T70	tradename 5405 5413	Oncaspar
T71	routeofadministration 5430 5446	intramuscularly,
T72	tradename 5609 5617	Oncaspar
T73	routeofadministration 5722 5736	intravenously,
T74	tradename 5737 5745	Oncaspar
T75	routeofadministration 5926 5937	intravenous
T76	tradename 6311 6319	Oncaspar
T77	tradename 7036 7044	Oncaspar
T78	activeingredient 7097 7111	L-asparaginase
T79	activeingredient 7165 7179	L-asparaginase
T80	activeingredient 7247 7261	L-asparaginase
T81	adversereaction 7304 7315	Anaphylaxis
T82	adversereaction 7320 7358	Serious Allergic Reactions Anaphylaxis
T83	adversereaction 7363 7389	serious allergic reactions
T84	tradename 7422 7430	Oncaspar
T85	adversereaction 7446 7472	serious allergic reactions
T86	activeingredient 7541 7556	L-asparaginase.
T87	tradename 7609 7617	Oncaspar
T88	adversereaction 7696 7707	anaphylaxis
T89	routeofadministration 7743 7754	intravenous
T90	tradename 7794 7802	Oncaspar
T91	adversereaction 7820 7847	serious allergic reactions.
T92	adversereaction 7853 7890	Thrombosis Serious thrombotic events,
T93	adversereaction 7901 7926	sagittal sinus thrombosis
T94	tradename 7960 7968	Oncaspar
T95	tradename 7983 7991	Oncaspar
T96	adversereaction 8009 8035	serious thrombotic events.
T97	adversereaction 8041 8066	Pancreatitis Pancreatitis
T98	tradename 8099 8107	Oncaspar
T99	tradename 8193 8201	Oncaspar
T100	adversereaction 8219 8232	pancreatitis.
T101	adversereaction 8238 8277	Glucose Intolerance Glucose intolerance
T102	tradename 8310 8318	Oncaspar
T103	adversereaction 8338 8357	glucose intolerance
T104	adversereaction 8380 8459	Coagulopathy Increased prothrombin time, increased partial thromboplastin time,
T105	adversereaction 8465 8483	hypofibrinogenemia
T106	tradename 8516 8524	Oncaspar
T107	adversereaction 8729 8742	coagulopathy.
T108	adversereaction 8748 8762	Hepatotoxicity
T109	adversereaction 8767 8805	Abnormal Liver Function Hepatotoxicity
T110	adversereaction 8810 8834	abnormal liver function,
T111	adversereaction 9343 9354	Anaphylaxis
T112	adversereaction 9359 9385	serious allergic reactions
T113	adversereaction 9432 9450	Serious thrombosis
T114	adversereaction 9497 9509	Pancreatitis
T115	adversereaction 9556 9575	Glucose intolerance
T116	adversereaction 9622 9634	Coagulopathy
T117	adversereaction 9681 9695	Hepatotoxicity
T118	adversereaction 9700 9723	abnormal liver function
T119	tradename 9801 9809	Oncaspar
T120	adversereaction 9814 9832	allergic reactions
T121	adversereaction 9844 9856	anaphylaxis)
T122	adversereaction 9858 9976	hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia, hepatotoxicity
T123	adversereaction 9981 10020	elevated transaminases. Hyperlipidemia
T124	adversereaction 10022 10042	hypercholesterolemia
T125	adversereaction 10047 10068	hypertriglyceridemia)
T126	tradename 10110 10119	Oncaspar.
T127	indication 10395 10398	ALL
T128	indication 10483 10486	ALL
T129	tradename 10500 10508	Oncaspar
T130	tradename 10836 10844	Oncaspar
T131	tradename 10897 10905	Oncaspar
T132	tradename 11100 11108	Oncaspar
T133	tradename 11394 11402	Oncaspar
T134	tradename 11455 11463	Oncaspar
T135	tradename 12176 12184	Oncaspar
T136	activeingredient 12193 12207	L-Asparaginase
T137	adversereaction 12223 12243	Abnormal Liver Tests
T138	adversereaction 12258 12281	Elevated Transaminases1
T139	adversereaction 12296 12314	Hyperbilirubinemia
T140	adversereaction 12330 12343	Hyperglycemia
T141	adversereaction 12358 12405	Central Nervous System Thrombosis Coagulopathy2
T142	adversereaction 12437 12449	Pancreatitis
T143	adversereaction 12576 12634	Prolonged prothrombin time or partial thromboplastin time;
T144	adversereaction 12638 12657	hypofibrinogenemia.
T145	tradename 12962 12970	Oncaspar
T146	adversereaction 12977 13000	elevated transaminases,
T147	adversereaction 13006 13019	coagulopathy,
T148	adversereaction 13024 13038	hyperglycemia,
T149	adversereaction 13043 13069	CNS thrombosis/hemorrhage,
T150	adversereaction 13074 13087	pancreatitis,
T151	adversereaction 13092 13119	clinical allergic reaction,
T152	adversereaction 13128 13147	hyperbilirubinemia,
T153	adversereaction 13179 13192	pancreatitis.
T154	indication 13213 13216	ALL
T155	indication 13335 13338	ALL
T156	tradename 13352 13360	Oncaspar
T157	tradename 13453 13461	Oncaspar
T158	indication 13507 13510	ALL
T159	tradename 13648 13656	Oncaspar
T160	adversereaction 13662 13689	clinical allergic reactions
T161	adversereaction 13691 13734	elevated transaminases, hyperbilirubinemia,
T162	adversereaction 13739 13754	coagulopathies.
T163	tradename 13802 13810	Oncaspar
T164	adversereaction 13826 13836	thrombosis
T165	adversereaction 13843 13856	hyperglycemia
T166	adversereaction 13893 13905	pancreatitis
T167	adversereaction 13917 13954	Allergic Reactions Allergic reactions
T168	adversereaction 13978 14037	bronchospasm, hypotension, laryngeal edema, local erythema
T169	adversereaction 14041 14065	swelling, systemic rash,
T170	adversereaction 14070 14080	urticaria.
T171	indication 14093 14096	ALL
T172	tradename 14107 14115	Oncaspar
T173	adversereaction 14154 14181	clinical allergic reactions
T174	adversereaction 14250 14267	allergic reaction
T175	indication 14577 14580	ALL
T176	indication 14614 14617	ALL
T177	activeingredient 14658 14671	asparaginase,
T178	activeingredient 14767 14782	L-asparaginase,
T179	activeingredient 14892 14907	L-asparaginase.
T180	adversereaction 14954 14981	clinical allergic reactions
T181	tradename 14985 14993	Oncaspar
T182	indication 15043 15046	ALL
T183	activeingredient 15091 15104	asparaginase,
T184	adversereaction 15135 15162	clinical allergic reactions
T185	tradename 15166 15174	Oncaspar
T186	adversereaction 15213 15241	CLINICAL ALLERGIC REACTIONS,
T187	tradename 15712 15720	Oncaspar
T188	tradename 16583 16591	Oncaspar
T189	tradename 16870 16878	Oncaspar
T190	tradename 17044 17052	Oncaspar
T191	tradename 17084 17092	Oncaspar
T192	tradename 17189 17197	Oncaspar
T193	tradename 17303 17311	Oncaspar
T194	tradename 17470 17478	Oncaspar
T195	tradename 17704 17712	Oncaspar
T196	dose 17895 17924	10,000 International Units/m2
T197	tradename 17928 17936	Oncaspar
T198	routeofadministration 17943 17954	intravenous
T199	adversereaction 17998 18024	increase in liver enzymes.
T200	adversereaction 18054 18058	rash
T201	tradename 18282 18290	Oncaspar
T202	nanoparticle 18292 18305	pegaspargase)
T203	activeingredient 18309 18323	L-asparaginase
T204	corecomposition 18325 18353	L-asparagine amidohydrolase)
T205	surfacecoating 18387 18425	monomethoxypolyethylene glycol (mPEG).
T206	activeingredient 18426 18440	L-asparaginase
T207	chemoclass 18457 18463	enzyme
T208	molecularweight 18531 18539	34.5 kDa
T209	surfacecoating 18587 18591	mPEG
T210	activeingredient 18606 18621	L-asparaginase;
T211	surfacecoating 18651 18655	mPEG
T212	molecularweight 18674 18680	5 kDa.
T213	tradename 18681 18689	Oncaspar
T214	activeingredient 18762 18776	L-asparaginase
T215	tradename 19054 19062	Oncaspar
T216	nanoparticle 19239 19252	pegaspargase,
T217	inactiveingredient 19253 19278	dibasic sodium phosphate,
T218	inactiveingredient 19294 19321	monobasic sodium phosphate,
T219	inactiveingredient 19341 19357	sodium chloride,
T220	inactiveingredient 19375 19380	water
T221	tradename 19480 19488	Oncaspar
T222	chemoclass 19818 19824	enzyme
T223	activeingredient 19825 19840	L-asparaginase,
T224	routeofadministration 20122 20135	intramuscular
T225	tradename 20145 20153	Oncaspar
T226	dose 20155 20184	2,500 International Units/m2)
T227	activeingredient 20587 20599	asparaginase
T228	indication 20707 20710	ALL
T229	routeofadministration 20732 20745	intramuscular
T230	dose 20764 20792	2,500 International Units/m2
T231	tradename 20824 20832	Oncaspar
T232	eliminationhalflife 20851 20859	5.8 days
T233	tradename 21120 21128	Oncaspar
T234	indication 21288 21291	ALL
T235	tradename 21301 21309	Oncaspar
T236	dose 21313 21341	2,500 International Units/m2
T237	routeofadministration 21342 21357	intramuscularly
T238	frequency 21358 21372	every 2 weeks.
T239	tradename 21397 21405	Oncaspar
T240	plasmahalflife 21410 21423	3.2  1.8 days
T241	activeingredient 21491 21505	L-asparaginase
T242	plasmahalflife 21510 21523	5.7  3.2 days
T243	auc 21620 21655	9.5  4.0 International Units/mL/day
T244	auc 21702 21737	9.8  6.0 International Units/mL/day
T245	tradename 22082 22090	Oncaspar
T246	tradename 22174 22182	Oncaspar
T247	indication 22396 22399	ALL
T248	tradename 22432 22440	Oncaspar
T249	indication 22630 22633	ALL
T250	tradename 22657 22665	Oncaspar
T251	activeingredient 22684 22698	L-asparaginase
T252	tradename 22731 22739	Oncaspar
T253	routeofadministration 22757 22772	intramuscularly
T254	dose 22786 22814	2,500 International Units/m2
T255	activeingredient 22936 22950	L-asparaginase
T256	routeofadministration 22968 22983	intramuscularly
T257	dose 22997 23025	6,000 International Units/m2
T258	frequency 23026 23044	three times weekly
T259	tradename 23268 23276	Oncaspar
T260	activeingredient 23296 23310	L-asparaginase
T261	activeingredient 23698 23710	asparaginase
T262	tradename 23786 23794	Oncaspar
T263	activeingredient 23814 23828	L-asparaginase
T264	activeingredient 24212 24226	L-Asparaginase
T265	tradename 24227 24235	Oncaspar
T266	activeingredient 24314 24328	L-Asparaginase
T267	tradename 24543 24551	Oncaspar
T268	dose 24553 24581	2,500 International Units/m2
T269	routeofadministration 24582 24596	intramuscular)
T270	activeingredient 24670 24684	L-asparaginase
T271	dose 24686 24714	6,000 International Units/m2
T272	routeofadministration 24715 24729	intramuscular)
T273	frequency 24747 24761	3 times weekly
T274	tradename 25025 25033	Oncaspar
T275	activeingredient 25104 25118	L-asparaginase
T276	tradename 25186 25194	Oncaspar
T277	activeingredient 25214 25228	L-asparaginase
T278	indication 25351 25354	ALL
T279	activeingredient 25382 25394	Asparaginase
T280	tradename 25427 25435	Oncaspar
T281	indication 25532 25546	acute leukemia
T282	indication 25562 25566	ALL]
T283	activeingredient 25621 25634	asparaginase.
T284	activeingredient 25655 25667	asparaginase
T285	activeingredient 25916 25931	L-asparaginase.
T286	tradename 25954 25962	Oncaspar
T287	dose 25976 26013	2,000 or 2,500 International Units/m2
T288	routeofadministration 26027 26042	intramuscularly
T289	routeofadministration 26046 26059	intravenously
T290	frequency 26060 26074	every 14 days.
T291	tradename 26093 26101	Oncaspar
T292	indication 26392 26395	ALL
T293	activeingredient 26434 26459	L-asparaginase-containing
T294	tradename 26543 26551	Oncaspar
T295	indication 26804 26807	ALL
T296	activeingredient 26847 26862	L-asparaginase.
T297	tradename 26902 26910	Oncaspar
T298	nanoparticle 26912 26925	pegaspargase)
T299	activeingredient 27027 27041	L-asparaginase
T300	tradename 27087 27095	Oncaspar
T301	tradename 27205 27213	Oncaspar
T302	adversereaction 27294 27320	Serious Allergic Reactions
T303	adversereaction 27359 27386	serious allergic reactions,
T304	adversereaction 27397 27409	anaphylaxis,
T305	adversereaction 27495 27505	Thrombosis
T306	adversereaction 27649 27661	Pancreatitis
T307	adversereaction 27747 27766	Glucose Intolerance
T308	company 27930 27962	Sigma-Tau Pharmaceuticals, Inc.,
